Q2 2025 · 13F-HR
SR ONE CAPITAL MANAGEMENT, LPholdings as filed
Filed 2025-08-14 · accession 0000950123-25-008422
$461.4M
Reported value
13
Positions
2025-06-30
Period end
The Brief · SR ONE CAPITAL MANAGEMENT, LP · Q2 2025
AI · grounded in 13F
SR ONE CAPITAL MANAGEMENT, LP established a new position in Arcellx, Inc. ACLXGBX valued at $154.5M. The fund also initiated new stakes in ARS Pharmaceuticals, Inc. SPRY for $70M and CRISPR Therapeutics AG CRSP for $51M. Additional new positions include Zenas BioPharma, Inc ZBIO at $47.6M and ORIC Pharmaceuticals, Inc. ORIC at $45.8M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03940C100 | ACLXGBX | Arcellx, Inc. | $154.5M | 33.5% | 2,346,630 | Common | SOLE |
| 82835W108 | SPRY | ARS Pharmaceuticals, Inc. | $70.0M | 15.2% | 4,012,903 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $51.0M | 11.1% | 1,048,951 | Common | SOLE |
| 98937L105 | ZBIO | Zenas BioPharma, Inc | $47.6M | 10.3% | 4,911,539 | Common | SOLE |
| 68622P109 | ORIC | ORIC Pharmaceuticals, Inc. | $45.8M | 9.93% | 4,514,929 | Common | SOLE |
| 603170101 | MLYS | Mineralys Therapeutics Inc. | $42.3M | 9.17% | 3,127,933 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $22.0M | 4.77% | 6,526,476 | Common | SOLE |
| H5870P102 | OCS | Oculis Holding AG | $6.3M | 1.36% | 322,500 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $5.9M | 1.27% | 1,959,896 | Common | SOLE |
| 65487U108 | NKTX | Nkarta, Inc. | $5.5M | 1.20% | 3,333,333 | Common | SOLE |
| 687604108 | ORKA | Oruka Therapeutics, Inc | $4.8M | 1.05% | 430,330 | Common | SOLE |
| 483119202 | KALAEUR | KALA Bio, Inc. | $2.9M | 0.62% | 598,940 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $2.7M | 0.59% | 747,750 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.